Additionally, the 36-month beta value for CKPT is 1.31. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for CKPT is 40.57M and currently, short sellers hold a 13.71% ratio of that float. The average trading volume of CKPT on November 27, 2024 was 707.06K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CKPT) stock’s latest price update
The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) has surged by 1.74 when compared to previous closing price of 4.03, but the company has seen a 21.30% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2024-11-14 that Checkpoint Therapeutics, Inc.’s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab’s unique mechanism and strong IP position offer substantial market opportunities in cSCC and beyond.
CKPT’s Market Performance
Checkpoint Therapeutics Inc (CKPT) has seen a 21.30% rise in stock performance for the week, with a 11.41% gain in the past month and a 84.68% surge in the past quarter. The volatility ratio for the week is 9.32%, and the volatility levels for the past 30 days are at 9.14% for CKPT. The simple moving average for the past 20 days is 16.41% for CKPT’s stock, with a 80.56% simple moving average for the past 200 days.
Analysts’ Opinion of CKPT
Many brokerage firms have already submitted their reports for CKPT stocks, with B. Riley Securities repeating the rating for CKPT by listing it as a “Buy.” The predicted price for CKPT in the upcoming period, according to B. Riley Securities is $7 based on the research report published on July 14, 2022 of the previous year 2022.
B. Riley Securities, on the other hand, stated in their research note that they expect to see CKPT reach a price target of $18. The rating they have provided for CKPT stocks is “Buy” according to the report published on June 09th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to CKPT, setting the target price at $16 in the report published on January 20th of the previous year.
CKPT Trading at 36.29% from the 50-Day Moving Average
After a stumble in the market that brought CKPT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.98% of loss for the given period.
Volatility was left at 9.14%, however, over the last 30 days, the volatility rate increased by 9.32%, as shares surge +6.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +62.70% upper at present.
During the last 5 trading sessions, CKPT rose by +21.30%, which changed the moving average for the period of 200-days by +106.03% in comparison to the 20-day moving average, which settled at $3.52. In addition, Checkpoint Therapeutics Inc saw 79.04% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CKPT starting from Oliviero James F III, who sale 24,610 shares at the price of $2.05 back on Jun 26 ’24. After this action, Oliviero James F III now owns 1,977,170 shares of Checkpoint Therapeutics Inc, valued at $50,450 using the latest closing price.
GRAY WILLIAM GARRETT, the Chief Financial Officer of Checkpoint Therapeutics Inc, sale 13,038 shares at $2.06 during a trade that took place back on Jun 26 ’24, which means that GRAY WILLIAM GARRETT is holding 672,186 shares at $26,858 based on the most recent closing price.
Stock Fundamentals for CKPT
Current profitability levels for the company are sitting at:
- -798.17 for the present operating margin
- -451.68 for the gross margin
The net margin for Checkpoint Therapeutics Inc stands at -988.68. The total capital return value is set at 2.98.
Currently, EBITDA for the company is -52.15 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 4098.73. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.29.
Conclusion
In conclusion, Checkpoint Therapeutics Inc (CKPT) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
